Muhammadiyah, known for its religious contributions, has expanded into the health startup space, notably with the biotech company PathGen. Founded in 2020, PathGen has quickly garnered attention, particularly after securing millions in venture capital (VC) funding from East Ventures and Royal Group in April 2024.

The funding has propelled PathGen’s efforts to revolutionize cancer diagnosis in Indonesia. The company focuses on molecular profiling and precision medicine, aiming to improve diagnostic accuracy and speed for cancer patients. Their innovative approach identifies specific molecular characteristics in cancer cells, allowing for targeted, personalized treatment.

Despite being relatively young, PathGen’s leadership has already made significant strides in the field. Co-founder and CEO Dr. Susanti recalls her journey of learning about investments and raising the initial seed funding for PathGen, which ultimately led to the successful VC funding. “I started with minimal knowledge, especially regarding investments, but through discussions with Mas Ghufron, we gained our first funding for PathGen,” she shared.

PathGen’s flagship product, BioColoMelt-Dx, a molecular diagnostic tool for colorectal cancer, has already made its way into prominent hospitals in Indonesia, including Dharmais Cancer Center and Cipto Mangunkusumo Hospital. This marks an important step for PathGen as they continue to build their ecosystem for oncology healthcare services.

In addition to its partnership with BioFarma for manufacturing and distribution, PathGen is also working towards democratizing molecular testing in Indonesia, aiming to make it accessible to a broader population.

SOURCE: MERDEKA | PHOTO: PATHGEN